Alopecia universalis: a patient's perspective of the cumulative life course impairment

Clin Exp Dermatol. 2021 Oct;46(7):1353-1354. doi: 10.1111/ced.14596. Epub 2021 Mar 19.

Authors

L J Burns¹, K E Flanagan¹, J T Pathoulas¹, A Ellison², N Mesinkovska^{2

3}, M M Senna^{1

4}

Affiliations

¹ Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA.
² National Alopecia Areata Foundation, San Rafael, CA, USA.
³ Department of Dermatology, University of California Irvine, Irvine, CA, USA.
⁴ Harvard Medical School, Boston, MA, USA.

PMID: 33740296
DOI: 10.1111/ced.14596

No abstract available

Publication types

Case Reports

MeSH terms

Adult
Alopecia / drug therapy
Alopecia / psychology*
Female
Humans
Janus Kinase Inhibitors / therapeutic use
Life Change Events*
Piperidines / therapeutic use
Pyrimidines / therapeutic use

Substances

Janus Kinase Inhibitors
Piperidines
Pyrimidines
tofacitinib

Supplementary concepts

Alopecia universalis